Is good science leading the way in the therapeutic use of psychedelic drugs?
Psychological Medicine October 1, 2022 DOI: 10.1017/s0033291722003191 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Keywords | Content measure theory Action physics |
| Citations | 18 |
Abstract
An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the 'Save PDF' action button.
Citations in the library
Cited by 16
- Single-Dose Psilocybin Treatment for Major Depressive Disorder JAMA August 31, 2023
- Randomized trial of ketamine masked by surgical anesthesia in patients with depression Nature Mental Health October 19, 2023
- Dark loops: contagion effects, consistency and chemosocial matrices in psychedelic-assisted therapy trials Psychological Medicine July 19, 2023
- Randomized Trial of Ketamine Masked by Surgical Anesthesia in Depressed Patients medRxiv Preprint Server April 28, 2023
- Attitudes toward psychedelics and psychedelic-assisted therapy among potential mental health service users and the general population in Australia. Australian & New Zealand Journal of Psychiatry October 1, 2024
and 11 more in the library
Cites 11
- Trial of Psilocybin versus Escitalopram for Depression New England Journal of Medicine April 14, 2021
- Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. Pharmacology & Therapeutics May 1, 2019
- Increased global integration in the brain after psilocybin therapy for depression. Nature Medicine April 11, 2022
- Therapeutic Applications of Classic Hallucinogens. Current Topics in Behavioral Neurosciences 2018
- Assessing the risk–benefit profile of classical psychedelics: a clinical review of second-wave psychedelic research Psychopharmacology January 13, 2022
and 6 more in the library